سعر رينفوك 15مجم 30 قرص 2024

Upadacitinib 15 mg prolonged-release tablets, pack of 30; selective JAK inhibitor for immune-mediated inflammatory diseases.

• Moderately to severely active rheumatoid arthritis with inadequate response or intolerance to one or more TNF blockersPopulation: AdultsDailyMed (US National Library of Medicine)
• Active psoriatic arthritis with inadequate response or intolerance to one or more TNF blockersPopulation: Adults and children 2 years and older (tablet for 30 kg and greater)DailyMed (US National Library of Medicine)
• Refractory moderate to severe atopic dermatitis not adequately controlled with other systemic drugsPopulation: Adults and children 12 years and olderDailyMed (US National Library of Medicine)

• Common (at least 1%) in RA/PsA/AS/nr-axSpA: upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, acne and headache.International label, same product · DailyMed (US National Library of Medicine)

• Known hypersensitivity to upadacitinib or any excipient.International label, same product · DailyMed (US National Library of Medicine)

• Boxed warning: serious bacterial, fungal, viral and opportunistic infections including tuberculosis; test for latent TB before and during therapy and interrupt treatment for serious infection.International label, same product · DailyMed (US National Library of Medicine)
• Boxed warning: higher all-cause mortality, malignancies (including lymphoma and lung cancer), major adverse cardiovascular events and thrombosis observed with another JAK inhibitor versus TNF blockers in RA patients.International label, same product · DailyMed (US National Library of Medicine)
• Serious hypersensitivity reactions, gastrointestinal perforations, hypoglycaemia in patients with diabetes and laboratory abnormalities (neutropenia, lymphopenia, anaemia, lipid and liver-enzyme elevations).International label, same product · DailyMed (US National Library of Medicine)

• Strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, grapefruit)Increase upadacitinib exposure; dose adjustments apply for AD, UC and CD; avoid grapefruit.DailyMed (US National Library of Medicine)
• Strong CYP3A4 inducers (e.g. rifampin)Decrease upadacitinib exposure; coadministration not recommended.DailyMed (US National Library of Medicine)

• Human data are insufficient; animal studies showed skeletal and cardiovascular malformations, so upadacitinib may cause fetal harm.International label, same product · DailyMed (US National Library of Medicine)
• Breastfeeding is not recommended during treatment and for 6 days after the last dose.International label, same product · DailyMed (US National Library of Medicine)

• Upadacitinib: Inhibits JAK enzymes, preventing phosphorylation and activation of STATs; greater potency at JAK1 than JAK2/JAK3/TYK2 in cellular assays.